Phase 2
N=36
Locomotor Training in Persons With Multiple Sclerosis
Multiple Sclerosis
Bottom Line
View on ClinicalTrials.gov: NCT00607126 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Aug 2016
Primary outcome: Primary: Walking Speed as Assessed by 25' Timed Walk — 22.7; 10.6; 23.9; 9.8 seconds
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Lokomat (Device); resistive training (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, Los Angeles
- Primary completion
- Aug 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Walking Speed as Assessed by 25' Timed Walk |
22.7; 10.6; 23.9; 9.8; 19.4; 9.6 | — |
| SECONDARY Distance |
367; 753; 474; 813; 436; 769 | — |
| SECONDARY Fatigue |
34.1; 37.7; 26.7; 29.4; 26.8; 29.9 | — |
| SECONDARY PASAT |
48.2; 46.8; 0.06; 0.42; 1.3; 0.58 | — |
Summary
Locomotor training is a new exercise modality that emphasizes task specificity to promote learning and neural plasticity. It has been reported to improve walking in patients with stroke, spinal cord injury and cerebral palsy. In this study, 40 patients with impaired ambulation due to Multiple Sclerosis will be randomized to receive 36 sessions of either locomotor training or an standard resistive exercise intervention.The locomotor training will be accomplished via a robotic device, the Lokomat, which will move the patient's legs on a treadmill while they are suspended in a harness.
Eligibility Criteria
Inclusion Criteria
- Persons with Secondary progressive or Primary Progressive Multiple Sclerosis who are ambulatory with difficulty and /or assistive device
Exclusion Criteria
- Ataxia
- Unable to ambulate
- Within 3 months of exacerbation
Data sourced from ClinicalTrials.gov (NCT00607126). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.